China Dasheng Biotechnology Company
Cycclone Inc., together with its subsidiaries, engages in the production, marketing, and distribution of bacteria based products used as additives for livestock feed and crop cultivation in the People's Republic of China. It provides artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends; and biological preservatives. The company offers AM/HM bacte… Read more
China Dasheng Biotechnology Company (CDBT) - Total Liabilities
Latest total liabilities as of December 2024: $1.18 Million USD
Based on the latest financial reports, China Dasheng Biotechnology Company (CDBT) has total liabilities worth $1.18 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
China Dasheng Biotechnology Company - Total Liabilities Trend (2006–2023)
This chart illustrates how China Dasheng Biotechnology Company's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
China Dasheng Biotechnology Company Competitors by Total Liabilities
The table below lists competitors of China Dasheng Biotechnology Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TALISMAN MINING (RJA.SG)
STU:RJA
|
Germany | €1.46 Million |
|
TANFIELD GRP
BE:XS3A
|
Germany | €72.00K |
|
Veltex Corporation
OTCQB:VLXC
|
USA | $3.93 Million |
|
Xebra Brands Ltd
OTCQB:XBRAF
|
USA | $638.28K |
|
PP LONDON SUMATRA (PS9A.SG)
STU:PS9A
|
Germany | €1.22 Trillion |
Liability Composition Analysis (2006–2023)
This chart breaks down China Dasheng Biotechnology Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China Dasheng Biotechnology Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China Dasheng Biotechnology Company (2006–2023)
The table below shows the annual total liabilities of China Dasheng Biotechnology Company from 2006 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-06-30 | $1.69 Million | +5535.93% |
| 2022-06-30 | $30.00K | -99.00% |
| 2008-06-30 | $2.99 Million | +3698.98% |
| 2007-10-31 | $78.82K | -98.40% |
| 2007-06-30 | $4.92 Million | +9892.06% |
| 2006-06-30 | $49.19K | -- |